Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Hum Reprod. 2011 Apr;26(4):885-97. doi: 10.1093/humrep/der010. Epub 2011 Feb 7.
BACKGROUND Enhanced proliferation and survival of eutopic endometrial cells from patients with endometriosis compared with healthy women is associated with abnormal activation of extra-cellular signal-regulated kinases 1 and 2 (ERK1/2). Given the role of Ras/Raf/mitogen-activated protein kinase (MAPK) and RhoA/ROCKII signalling pathways in the regulation of cell proliferation and migration, we analysed their possible roles in endometriosis. METHODS Primary eutopic endometrial stromal cells of patients with endometriosis (Eu-hESC, n= 16) and endometriosis-free controls (Co-hESC, n= 14) were harvested and subjected to proliferation and migration assays as well as kinase activity assays and immunoblot analysis of proteins from the Ras/Raf/MAPK and RhoA/ROCKII signalling pathways. Effects of ROCKII (Y-27632) and MAPK (U0126) inhibitors or siRNA knockdown of ROCKII, Raf-1 and B-Raf were analysed. RESULTS The proliferation rate of Eu-hESC was 54% higher than Co-hESC. Eu-hESC also displayed a 75% higher migration rate than Co-hESC. Eu-hESC displayed higher levels of ERK phosphorylation (83%) and p27 expression (61%) and lower levels of Raf-1 protein (47%) compared with controls. In addition to an inhibitory effect on cell proliferation, ROCKII knockdown led to significant down-regulation of cyclinD1 and p27 but did not affect ERK phosphorylation. Down-regulation of Raf-1 by siRNA was dispensable for cell proliferation control but led to an increase in ROCKII activity and a decrease in cell migration. B-Raf was shown to act as a regulator of hESC proliferation by modulating cellular ERK1/2 activity and cyclinD1 levels. Eu-hESC displayed 2.4-fold higher B-Raf activity compared with Co-hESC and therefore exhibit abnormally activated Ras/Raf/MAPK signalling. CONCLUSIONS We show that the same molecular mechanisms operate in Co- and Eu-hESC. The differences in cell proliferation and migration between both cell types are likely due to increased activation of Ras/Raf/MAPK and RhoA/ROCKII signalling pathways in cells from endometriosis patients.
与健康女性相比,患有子宫内膜异位症的患者的在位子宫内膜细胞的增殖和存活增强,这与细胞外信号调节激酶 1 和 2(ERK1/2)的异常激活有关。鉴于 Ras/Raf/丝裂原活化蛋白激酶(MAPK)和 RhoA/ROCKII 信号通路在细胞增殖和迁移的调节中的作用,我们分析了它们在子宫内膜异位症中的可能作用。
从子宫内膜异位症患者(Eu-hESC,n=16)和无子宫内膜异位症对照者(Co-hESC,n=14)中采集原发性在位子宫内膜基质细胞,并进行增殖和迁移测定,以及 Ras/Raf/MAPK 和 RhoA/ROCKII 信号通路的蛋白激酶活性测定和免疫印迹分析。分析 ROCKII(Y-27632)和 MAPK(U0126)抑制剂或 ROCKII、Raf-1 和 B-Raf 的 siRNA 敲低的作用。
Eu-hESC 的增殖率比 Co-hESC 高 54%。Eu-hESC 的迁移率也比 Co-hESC 高 75%。与对照组相比,Eu-hESC 显示 ERK 磷酸化(83%)和 p27 表达(61%)水平较高,而 Raf-1 蛋白水平(47%)较低。除了对细胞增殖有抑制作用外,ROCKII 敲低还导致 cyclinD1 和 p27 的显著下调,但不影响 ERK 磷酸化。siRNA 下调 Raf-1 对细胞增殖控制不是必需的,但会导致 ROCKII 活性增加和细胞迁移减少。B-Raf 通过调节细胞内 ERK1/2 活性和 cyclinD1 水平来调节 hESC 增殖,被证明是 hESC 增殖的调节剂。与 Co-hESC 相比,Eu-hESC 显示出 2.4 倍高的 B-Raf 活性,因此表现出异常激活的 Ras/Raf/MAPK 信号通路。
我们表明,相同的分子机制在 Co-hESC 和 Eu-hESC 中起作用。两种细胞类型之间的细胞增殖和迁移差异可能是由于子宫内膜异位症患者的细胞中 Ras/Raf/MAPK 和 RhoA/ROCKII 信号通路的激活增加所致。